Effect of Carfilzomib on Proliferation and Apoptosis of Mantle Cell Lymphoma Cells.
10.19746/j.cnki.issn.1009-2137.2019.03.030
- Author:
Guo-Xiong JIANG
1
;
Dong-Ya LI
2
;
Ming CHEN
2
;
Yi-Chen LIU
2
;
Ji-Xiang CHEN
3
;
Xiao-Feng SHI
4
,
5
Author Information
1. Department of Hematology，Affiliated Hospital of Jiangsu University，Zhenjiang 212000，Jiangsu Province，China,Department of General Surgery，Jiangdu People＇s Hospital of Yangzhou，Yangzhou 225200，Jiangsu Province，China.
2. Department of Hematology，Affiliated Hospital of Jiangsu University，Zhenjiang 212000，Jiangsu Province，China.
3. Department of General Surgery，Affiliated Hospital of Jiangsu University，Zhenjiang 212000，Jiangsu Province，China.
4. Department of Hematology，Affiliated Hospital of Jiangsu University，Zhenjiang 212000，Jiangsu Province，China,E-mail：shixiaofeng1977@
5. com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
Apoptosis;
Bortezomib;
Cell Line, Tumor;
Cell Proliferation;
Humans;
Lymphoma, Mantle-Cell;
Oligopeptides
- From:
Journal of Experimental Hematology
2019;27(3):827-832
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of Carfilzomib on mantle cell lymphoma (MCL), and to compare with effect of Bortezomib.
METHODS:The Jeko-1 cells and primary MCL cells were treated with Carfilzomib for 24, 48 and 72 h, then the inhibitory rate was detected using CCK-8. Lymphocytes derived from healthy volunteer were served as cell controls. Bortezomib and Cyclophosphamide (CTX) were served as medicinal controls. At the same time, the apoptosis of cells treated with different drugs was detected using flow cytometry.
RESULTS:The inhibitory effect of Carfilzomib on Jeko-1 cells and primary MCL cells was exhibited with time-dependent and concentration-dependent manners (P＜0.01, r=0.393, r=0.650, rJ=0.473, r=0.417), but the effect on lymphocytes derived from healthy volunteer only showed time-dependence (P＜0.01, r=0.928). Under the same concentration, Carfilzomib exhibited the proliferation Jeko-1 cells stronger than Bortezomib (P＜0.01), but the same inhibition on primary MCL cells was not significantly different from that on lymphocytes derived from healthy volunteer (P＞0.05). Under clinical recommended concentration, Carfilzomib had a stronger inhibitory effect on primary MCL cells than that of Bortezomib (P＜0.01). Cell apoptosis assay showed that under the same concentration the ability of Carfilzomib to induce cell apoptosis was significantly stronger than that of Bortezomib (P＜0.05).
CONCLUSION:Carfilzomib can inhibit the growth of MCL cells, its inhibitory rate on the MCL cells is higher than that of Bortezomib.
